BioSpace News Archive

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in the Phase 3 LIBRA clinical trial of TP-03 in Chinese patients with Demodex blepharitis.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2022.

TFF Pharmaceuticals, Inc. announced program updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder clinical programs.

Heron Therapeutics, Inc. (Nasdaq: HRTX) today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 4:30 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.

Pear Therapeutics, Inc. (Nasdaq: PEAR) today announced the company will participate in the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California.

AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management and post-operative pain management, announced third quarter 2022 financial results.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced the appointment of Dr. Nat Calloway to its Board of Directors.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2022.

Amcor CEO Ron Delia said: “Amcor delivered a strong first quarter highlighted by solid operating leverage with 3% organic sales growth driving a 10% increase in adjusted earnings per share on a comparable constant currency basis.